Alfons Billiau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2524094/publications.pdf

Version: 2024-02-01

44 papers 3,193 citations

30 h-index 253896 43 g-index

44 all docs

44 docs citations

44 times ranked 3195 citing authors

#	Article	IF	CITATIONS
1	At the Centennial of the Bacteriophage: Reviving the Overlooked Contribution of a Forgotten Pioneer, Richard Bruynoghe (1881–1957). Journal of the History of Biology, 2016, 49, 559-580.	0.2	12
2	Pulmonary inflammation in mice with collagenâ€induced arthritis is conditioned by complete <scp>F</scp> reund's adjuvant and regulated by endogenous <scp>IFN</scp> â€Î³. European Journal of Immunology, 2012, 42, 3223-3234.	1.6	26
3	A Tale of Two Interferon Bioassays: How Frustration with Discrepant Results from Slightly Dissimilar Methods Can Engender Discovery. Methods in Molecular Biology, 2012, 820, 1-6.	0.4	O
4	Collagen-Induced Arthritis as an Animal Model for Rheumatoid Arthritis: Focus on Interferon- \hat{l}^3 . Journal of Interferon and Cytokine Research, 2011, 31, 917-926.	0.5	88
5	Collagen-induced arthritis and related animal models: How much of their pathogenesis is auto-immune, how much is auto-inflammatory?. Cytokine and Growth Factor Reviews, 2011, 22, 339-344.	3.2	49
6	Interferon- \hat{l}^3 : A historical perspective. Cytokine and Growth Factor Reviews, 2009, 20, 97-113.	3.2	356
7	How interferon- \hat{l}^3 keeps autoimmune diseases in check. Trends in Immunology, 2008, 29, 479-486.	2.9	159
8	Protective role of IFN-Î ³ in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. Journal of Leukocyte Biology, 2007, 81, 1044-1053.	1.5	41
9	Interferons: The pathways of discovery. Journal of Clinical Virology, 2007, 39, 241-265.	1.6	7
10	Interferon: The pathways of discovery. Cytokine and Growth Factor Reviews, 2006, 17, 381-409.	3.2	42
11	Anti-inflammatory properties of Type I interferons. Antiviral Research, 2006, 71, 108-116.	1.9	78
12	Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Research, 2005, 7, R402.	2.0	143
13	Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Research, 2004, 6, R220.	2.0	59
14	Dependence on interferon- \hat{I}^3 for the spontaneous occurrence of arthritis in DBA/1 mice. Arthritis and Rheumatism, 2003, 48, 2983-2988.	6.7	22
15	Mac-1+ myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-γ in autoimmune disease models. Trends in Immunology, 2001, 22, 367-371.	2.9	47
16	Protein disulfide isomerase-mediated cell-free assembly of recombinant interleukin-12 p40 homodimers. FEBS Journal, 2000, 267, 6679-6683.	0.2	15
17	In VivoNeutrophil Recruitment by Granulocyte Chemotactic Protein-2 Is Assisted by Gelatinase B/MMP-9 in the Mouse. Journal of Interferon and Cytokine Research, 2000, 20, 667-674.	0.5	69
18	Transcriptional control of the human MCP-2 gene promoter by IFN- \hat{l}^3 and IL- $1\hat{l}^2$ in connective tissue cells. Journal of Leukocyte Biology, 1999, 66, 502-511.	1.5	15

#	Article	IF	Citations
19	GroEL/ES chaperonins protect interferon-gamma against physicochemical stress. Study of tertiary structure formation by alpha-casein quenching and ELISA. FEBS Journal, 1998, 251, 181-188.	0.2	9
20	Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN- \hat{l}^3 receptor-deficient mice. European Journal of Immunology, 1998, 28, 2143-2151.	1.6	99
21	Production and Characterization of Recombinant Active Mouse Gelatinase B from Eukaryotic Cells and in vivo Effects after Intravenous Administration. FEBS Journal, 1997, 244, 21-30.	0.2	40
22	Cloning, Bacterial Expression and Biological Characterization of Recombinant Human Granulocyte Chemotactic Protein-2 and Differential Expression of Granulocyte Chemotactic Protein-2 and Epithelial Cell-Derived Neutrophil Activating Peptide-78 mRNAs. FEBS Journal, 1997, 243, 762-769.	0.2	28
23	Potential therapeutic use of antibodies directed towards HuIFN-γ. Biotherapy (Dordrecht,) Tj ETQq1 1 0.784314	rgBT/Ov	erlock 10 Tf 5
24	Interferon-Î ³ : Biology and Role in Pathogenesis. Advances in Immunology, 1996, 62, 61-130.	1.1	376
25	Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-l³. European Journal of Immunology, 1996, 26, 2393-2398.	1.6	126
26	Essential role for natural killer cells in the lethal lipopolysaccharide-induced Shwartzman-like reaction in mice. European Journal of Immunology, 1994, 24, 1155-1160.	1.6	87
27	Natural human monocyte gelatinase and its inhibitor. FEBS Letters, 1991, 284, 73-78.	1.3	46
28	The neutrophil-activating proteins interleukin 8 and \hat{l}^2 -thromboglobulin:in vitro andin vivo comparison of NH2-terminally processed forms. European Journal of Immunology, 1990, 20, 2113-2118.	1.6	91
29	Purification of granulocyte chemotactic peptide/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of beta-thromboglobulin. FEBS Journal, 1989, 181, 337-344.	0.2	94
30	Simultaneous production of interleukin 6, interferon-β and colony-stimulating activity by fibroblasts after viral and bacterial infection. European Journal of Immunology, 1989, 19, 163-168.	1.6	91
31	The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. European Journal of Immunology, 1989, 19, 1189-1194.	1.6	136
32	Identification by sequence analysis of chemotactic factors for monocytes produced by normal and transformed cells stimulated with virus, double-stranded RNA or cytokine. European Journal of Immunology, 1989, 19, 2367-2373.	1.6	93
33	The Potential Role of Interferons and Interferon Antagonists in Inflammatory Disease. Drugs, 1989, 38, 957-972.	4.9	28
34	Heterogeneity of human tissue-type plasminogen activator. FEBS Letters, 1988, 238, 129-134.	1.3	6
35	Interferons and Inflammation. Journal of Interferon Research, 1987, 7, 559-567.	1.2	35
36	Anti-interferon- \hat{l}^3 antibody protects mice against the generalized Shwartzman reaction. European Journal of Immunology, 1987, 17, 1851-1854.	1.6	93

#	Article	IF	CITATION
37	Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6). FEBS Journal, 1987, 168, 543-550.	0.2	92
38	Activation of natural cytotoxicity of human peripheral blood mononuclear cells by interferon: a kinetic study and comparison of different interferon types. British Journal of Haematology, 1982, 50, 85-94.	1.2	35
39	Inferferon induced in human leukocytes by concanavalin A: isolation and characterization of \hat{I}^3 - and \hat{I}^2 -type components. European Journal of Immunology, 1981, 11, 937-942.	1.6	54
40	[13] Large-scale production of human fibroblast interferon. Methods in Enzymology, 1981, 78, 101-119.	0.4	22
41	Interferon induced in human leukocytes by mitogens: production, partial purification and characterization. European Journal of Immunology, 1980, 10, 877-883.	1.6	136
42	Human Fibroblast Interferon for Clinical Trials: Production, Partial Purification, and Characterization. Antimicrobial Agents and Chemotherapy, 1979, 16, 49-55.	1.4	51
43	Human Fibroblast Interferon for Clinical Trials: Pharmacokinetics and Tolerability in Experimental Animals and Humans. Antimicrobial Agents and Chemotherapy, 1979, 16, 56-63.	1.4	79
44	Influence of Basic Substances on the Induction of the Interferon Mechanism. Annals of the New York Academy of Sciences, 1970, 173, 657-667.	1.8	11